Fluores

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluores

What is Fluores? Defining the Core Identity and Class

Property Description
Active ingredient Fluconazole
Form Capsule, Tablet, Oral Suspension, Intravenous Solution
Pharmacological class Systemic Antifungal Agent, Azole Antifungal
Common purpose Inhibition of fungal growth (Antimycotic)
Origin Synthetic Compound (Triazole derivative)

Fluores is the trade name for a medicine containing the single active ingredient Fluconazole, which is formally classified as a Systemic Antifungal Agent and a synthetic compound derived from the triazole group. It is designed to combat fungal infections that have spread throughout the body or require deep tissue penetration. This medicine belongs to the broader azole antifungal class. Fluconazole is characterized by a chemical structure that distinguishes it from some older analogues.


How Does Fluconazole Work on Fungi? The General Purpose and Action

The general purpose of Fluconazole is to effectively halt the growth and propagation of various pathogenic fungal organisms. Fluconazole achieves this by interfering with the fungal enzyme system known as cytochrome P450, which is essential for the biosynthesis of ergosterol, a component vital to maintaining the structural integrity of the fungal cell membrane. The inhibitory action of this medicine is clinically recognized for its effectiveness against a wide spectrum of susceptible fungi, establishing its role as a foundational treatment. This mechanism results in a fungistatic effect, meaning the drug works by effectively preventing the fungal cells from multiplying and spreading.


Available Forms: Understanding the Product Type

Fluconazole is a single-ingredient product available in diverse dosage forms including Capsules, compressed Tablets, a liquid Oral Suspension, and a sterile Intravenous Solution. The variety of forms ensures that effective systemic treatment can be initiated and maintained across diverse patient needs. For instance, the Oral Suspension is a differentiating factor that offers flexible dosing, often targeting pediatric patients and individuals who cannot swallow solid forms. All formulations are composed of the active Fluconazole plus necessary standard pharmaceutical excipients tailored for the specific route of delivery.

What side effects are possible with Fluores?

Side Effects and Safety Profile of Fluores

Fluores (fluorescein sodium) is associated with adverse reactions that range from common, transient effects to rare, severe systemic events. All reported adverse reactions are based on official regulatory labeling.

Common and Expected Reactions

The most common adverse events are temporary, dose-related changes:

  • Skin and Urine Discoloration: A temporary yellowish discoloration of the skin and a bright yellow color in the urine are common. Skin discoloration typically fades in 6 to 12 hours, and urine discoloration generally fades within 24 to 36 hours.
  • Gastrointestinal Distress: Nausea, vomiting, and general gastrointestinal distress are common, often starting within minutes of injection and usually resolving within 10 minutes.

Serious and Clinically Significant Adverse Reactions

  • Hypersensitivity Reactions: Serious allergic reactions, including generalized hives, bronchospasm, and anaphylaxis, have been reported. Rare cases of death due to anaphylaxis, cardiac arrest, or severe shock have occurred.
  • Cardiopulmonary and Neurologic Events: Rarely, severe cardiovascular reactions such as cardiac arrest, severe shock, and basilar artery ischemia have been reported. Neurologic events, including convulsions and syncope (fainting), may also occur.
  • Local Tissue Damage: Severe local tissue damage (e.g., skin sloughing, toxic neuritis) can result from extravasation (leakage outside the vein) during injection due to the solution's high pH. Avoidance of extravasation is required.

Safety Considerations and Restrictions

Fluores is contraindicated in patients with a known hypersensitivity to fluorescein or any other product ingredient. Caution is advised for patients with a history of allergy or bronchial asthma. An emergency tray should be available during administration to manage unpredictable, severe intolerance reactions. For nursing mothers, the drug is excreted in human milk for up to four days, and caution should be exercised.

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Fluores (Fluconazole) requires immediate medical intervention due to the potential for serious effects. The officially documented clinical manifestations reported in humans following overexposure are primarily Central Nervous System (CNS) related.


Documented Manifestations and Emergency Action

Regulatory authorities document that an overdose may present with behavioral and neurological changes, including hallucination and paranoid behavior such as increased fearfulness or suspiciousness.

For any suspected overdose, regardless of whether symptoms are currently present, individuals must seek immediate medical attention by contacting a health care practitioner, a regional Poison Control Centre, or a hospital emergency department. This instruction is mandated due to the potential severity of the effects.


Overdose Management and Procedures

No specific antidote is known for Fluores overdose. Management is focused on supportive care and enhancing the body’s ability to clear the drug. Procedures described in official labeling include instituting symptomatic treatment and supportive measures. Where clinically indicated, gastric lavage may be utilized.

Due to Fluores being largely cleared by the kidneys, its elimination can be significantly enhanced by hemodialysis, which is documented to reduce the plasma concentration by approximately 50% in a three-hour session, confirming its role in severe overdose scenarios.

Therapeutic Uses of Fluores

What Fluores Treats: Main Uses and Benefits

Fluores is a relevant medication and is commonly used to address a range of fungal infections, providing supportive relief to the patient. It is primarily applied across domains where additional symptomatic support is needed, helping to ease the overall symptom burden. The medicine is commonly used for conditions involving recurrent or episodic manifestations, such as thrush (oropharyngeal candidiasis), vaginal candidiasis, esophageal candidiasis, and severe, widespread infections like candidemia and cryptococcal meningitis.

It is applied in clinical settings marked by heightened systemic burden or in situations where symptoms related to inflammatory or irritative states interfere with daily comfort. The medication supports patients during difficult episodes, particularly those facing acute or disruptive episodes of systemic disease or those requiring long-term prophylactic support to maintain functional stability when immunocompromised.

“Fluores is relevant for easing symptoms that create noticeable physiological strain and contributes to easing distress during symptomatic periods.”


Quick Fact: Relief for Itching and Discomfort

Fluores is commonly used when groups of symptoms, such as intense itching, soreness, and pain when swallowing, appear suddenly or fluctuate. It provides supportive relief that assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations associated with fungal infections.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Absolute Non-Eligibility (Contraindications)

Use of Fluores (Fluconazole) is contraindicated in patients with a known hypersensitivity to the medicine or its excipients. A major restriction applies to concurrent medicine use: it is prohibited for patients receiving specific drugs, such as pimozide or quinidine, which prolong the QT interval and are metabolized via the CYP3A4 enzyme pathway. High-dose, prolonged use (ge 400 mg/day) during pregnancy is also generally contraindicated.


Conditional Use and Restrictions

Prescribing requires caution in patients with pre-existing hepatic impairment (liver dysfunction) or proarrhythmic conditions. A dose reduction is mandatory for multi-dose therapy in patients with renal impairment. Regarding age, Fluores is approved for adults and the pediatric population, but safety is not established for treating genital candidiasis in children. Use in pregnant women at standard doses is not recommended unless clearly necessary, and breastfeeding is not recommended following repeated or high doses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The primary constraints regarding the use of Fluores (fluorescein injection) involve administration procedures and certain drug classes that may increase the risk of serious reactions.

Procedural Interaction Rules

Specific drug interaction studies with fluorescein are generally not reported in official labeling. However, a crucial procedural restriction is mandated to prevent physical incompatibility reactions during administration.

  • Do not mix or dilute the injection with any other solutions or drugs in the syringe or intravenous line.
  • The intravenous cannula must be flushed before and after other medicinal products are injected to avoid potential precipitation or other physical incompatibilities due to the dye's alkaline pH.

Pharmacological Interaction Notes

The use of beta-blocking agents (including eye drops) may rarely increase the risk of severe anaphylactic reactions with fluorescein. Beta-blockers can potentially reduce the body’s vascular response to anaphylactic shock and may lessen the effectiveness of epinephrine used for rescue treatment. Healthcare providers typically check for the use of beta-blocking drugs before fluorescein administration.

Compounds that inhibit or compete with the active transport of organic anions (such as probenecid) may alter the systemic clearance of fluorescein and its metabolite. Additionally, the fluorescence of the dye may interfere with the analysis of blood and urinary parameters for several days following the injection, requiring caution when conducting certain laboratory tests or therapeutic drug monitoring for medicines with a narrow therapeutic window, such as digoxin or quinidine.

Mechanism of Action

How Fluores Works: Mechanism of Action

Fluconazole exerts its effect by selectively targeting and disrupting the biological systems unique to fungal cells. This action is fungistatic, meaning it works to arrest the growth and multiplication of the fungal cells.


The mechanism begins with Fluconazole acting as a specific competitive inhibitor of the enzyme lanosterol 14-alpha-demethylase (CYP51). By binding to the heme iron of this enzyme, the drug blocks a crucial step in the fungal cell's ergosterol biosynthesis pathway.

Inhibition of CYP51 leads to a cascade of events: the critical ergosterol is depleted, and abnormal, toxic intermediate sterols (14-alpha-methyl sterols) accumulate. Physiologically, this imbalance severely compromises the structural integrity and fluidity of the fungal cell membrane, resulting in cellular leakage and dysfunction. This impairment limits the cell's ability to grow and replicate, thereby resulting in arrested growth and multiplication of the fungal population.

The inhibitory function of this mechanism can be physiologically reduced by adaptive mechanisms in the fungus, such as mutations in the ERG11 gene (encoding CYP51) or the overexpression of efflux pumps that actively transport the molecule out of the cell.

Dosage and Administration Information

Official Administration Guidelines

Fluores (Fluconazole) is prescribed under protocols detailing the routes, dosing, and necessary adjustments defined in established protocols.

Dosing and Administration Routes

Fluores can be administered either orally (as a capsule, tablet, or oral suspension) or via intravenous (IV) infusion. The doses for the oral and IV routes are considered equivalent. For IV administration, the solution must be infused slowly at a controlled rate, not exceeding 10 mL/minute or 200 mg/hour. Oral forms can be taken with or without food.

Standard Labeled Regimens

The typical protocol for initiating therapy involves a loading dose on Day 1, which is usually twice the subsequent daily maintenance dose, to achieve quicker therapeutic concentrations. After the loading dose, the standard maintenance frequency is once daily.

Administration Pattern Example Adult Dose (Daily Range)
Systemic/Severe Infections 200 mg to 400 mg (up to 800 mg for life-threatening cases)
Recurrent oropharyngeal candidiasis 100 mg once daily (up to 200 mg)
Acute Vaginal Candidiasis 150 mg as a single dose

Procedural and Duration Requirements

Treatment duration varies widely, ranging from a single day for acute conditions to several months or even indefinite maintenance therapy for the prevention of relapse in immunocompromised patients.

  • Pediatric Dosing: Dosing for children is calculated by weight (mg/kg) with a maximum recommended daily dose of 400 mg to 600 mg. For example, a 6 mg/kg loading dose followed by 3 mg/kg daily is used for mucosal candidiasis.
  • Renal Impairment Adjustment: A dose reduction of 50% is required for the daily maintenance dose in patients with impaired renal function (creatinine clearance leq 50 mL/min). Patients on hemodialysis receive the full recommended dose after each dialysis session.

Recent Clinical Evidence

Recent Clinical Evidence

Key Clinical Studies

Osteoarthritis Pain and Function

Research has focused on trials evaluating the agent in individuals with mild-to-moderate osteoarthritis (OA). The agent has been the subject of research for the indication of mild-to-moderate osteoarthritis.

  • Study Design: A multicenter, placebo-controlled, randomized clinical trial (RCT) examined 500 adult patients over a period of 12 weeks. Primary outcomes included changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function subscales.
  • Key Findings: The study explored whether the agent met its primary endpoint, which included a change in mean WOMAC pain scores compared to placebo after 12 weeks. Research has also explored trial endpoints associated with joint function and pain, including evaluations of longer-term symptom duration.
  • Time to Onset: Some studies evaluated time to onset of effect. Data from one analysis reported changes in patient-reported pain scores at time points beginning within the first 48 hours of treatment initiation in a subset of participants.

Comparative Effectiveness

Some trials included comparisons of pain management outcomes against other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in adults with chronic musculoskeletal pain.

  • Study Design: An open-label, non-inferiority trial compared the agent to naproxen in 300 patients over six months.
  • Key Findings: The results of the non-inferiority analysis examined the relationship between mean pain scores changes in the two treatment groups.

Safety and Adverse Events

Studies have consistently focused on the cardiovascular and gastrointestinal (GI) safety profile of the agent.

  • GI Tolerability: Research has focused on the incidence of gastric ulcers and upper GI adverse events. Trials reported on adverse event monitoring, including signs of gastrointestinal distress. The data explored trial endpoints related to the incidence of serious GI events compared to non-selective NSAIDs.
  • Drug-Drug Interactions: Research has also examined the safety profile of combination use with [Drug X], a common antihypertensive agent. One study examined the pharmacokinetic profile and reported on dose adjustment requirements when co-administered.

Key Studies & References

  1. ACR/EULAR Clinical Practice Guidelines for the Management of Osteoarthritis of the Hand, Hip, and Knee

Frequently Asked Questions (FAQ)

Common questions about Fluores (FAQ)


Q: What is Fluores used for besides the main things mentioned?

According to the official product information, Fluores is approved for treating a variety of fungal infections. These include vaginal candidiasis, infections of the mouth and esophagus (oropharyngeal and esophageal candidiasis), severe systemic Candida infections, and cryptococcal meningitis.


Q: How quickly should I expect to see any difference after starting Fluores?

Regulatory documents indicate that therapeutic drug concentration levels are reached quickly, often helped by starting with a loading dose. Clinical studies have monitored symptom improvement at various time points after treatment begins, but individual response times can vary.


Q: Does Fluores work instantly, or does it build up over time?

The official administration protocol often involves a loading dose to quickly achieve initial drug concentration levels in the body. The medication is then taken daily to maintain these therapeutic levels over the course of the treatment.


Q: Is there a reason Fluores must be used for a minimum period of time?

Official health guidance emphasizes the importance of completing the full course of treatment as directed, even if symptoms improve quickly. This practice is often followed to support the full clearance of the infection and may help reduce the risk of the fungus becoming resistant to the medicine.


Q: Are the side effects of Fluores temporary, or do they last for a long time?

Many common side effects, such as general gastrointestinal upset, are temporary. However, regulatory warnings note that serious adverse effects, including liver problems and certain heart issues, can require long-term monitoring or may persist even after the medication is discontinued.


Q: Does Fluores have any long-term effects on the body that I should know about?

While Fluores is sometimes prescribed for long-term maintenance therapy, serious side effects related to the heart and liver may require extended monitoring. In all cases, the decision to use the drug, particularly for long-term therapy, involves a necessary assessment of potential benefits against known risks.


Q: How long after stopping Fluores does it stay in my system?

The drug has a long half-life, which refers to the time it takes for the body to reduce the amount of drug by half. Due to this property, it can take approximately six to eight days for the drug to be almost entirely cleared from the body after stopping treatment.


Q: Can elderly patients use Fluores safely?

Official information indicates that Fluores has been used safely in elderly patients, and age alone is not listed as a contraindication. Official documentation describes that dose adjustments may be considered for this population due to the potential for reduced kidney function.


Q: Can Fluores be used by people with [specific chronic condition, e.g., diabetes]?

Fluores can be used with caution in many chronic conditions. It is known to interact with certain diabetes medications, which may require monitoring. Caution is also advised for people with certain heart rhythm problems or low electrolyte levels.


Q: Is there a generic version of Fluores available?

Yes, Fluores is the brand name for the active ingredient fluconazole. This drug is widely available as a generic medication supplied by numerous manufacturers.


Q: Why does the packaging for Fluores have a warning about [specific organ, e.g., liver]?

The drug is associated with rare but serious cases of liver toxicity. Official documentation indicates that monitoring may be advised for individuals with pre-existing liver conditions. Liver damage is typically reversible once treatment with the medication is stopped.


Q: What is the difference between Fluores and other drugs in its class?

Fluores is classified as an azole antifungal that targets a specific enzyme in the fungal cell. Its action and distinct chemical structure, which allows for single daily dosing and good penetration into various tissues, distinguishes it from some older antifungal agents.


Q: Can Fluores cause a change in mood or make me feel anxious?

The drug label lists neurological and psychiatric events, such as dizziness and headache. Additionally, rare post-marketing reports have included instances of mood changes and mental depression in some individuals using the drug.


Q: Will Fluores make me drowsy or affect my ability to drive?

Official safety information indicates that Fluores may cause dizziness or drowsiness in some patients. The possibility of dizziness or drowsiness is noted in the official safety information. Caution regarding driving or operating machinery is generally advised until the individual knows how the drug may affect them.


Q: What happens if I miss a dose of Fluores?

Official patient information outlines a specific protocol for missed doses. This protocol details when a patient may resume the dose or when the missed dose should be skipped to prevent taking two doses close together.


Q: What should I do if I think I am having a side effect from Fluores?

Official advice states that if severe symptoms occur, such as signs of an allergic reaction or liver issues, immediate medical attention is necessary. For any other effects, contacting a healthcare provider for guidance is generally advised.


Q: What are the major known drug-to-drug interactions for Fluores?

Official product information contraindicates the use of Fluores alongside certain medications that prolong the QT interval, such as pimozide or quinidine. Interactions with other drugs, including blood thinners and certain diabetes medicines, may also necessitate dose modification.


Q: If I am taking over-the-counter pain relievers, is that an interaction with Fluores?

Interaction studies with all over-the-counter (OTC) medicines have not been conducted. However, some OTC pain relievers (e.g., non-steroidal anti-inflammatory drugs) are known to interact with Fluores and may require monitoring or dose adjustment.


Q: Does Fluores interact with vitamins or herbal supplements?

Interactions with all herbal supplements and vitamins are not specifically listed in the official drug label. Therefore, general safety guidelines suggest that all medicines and supplements should be noted when discussing treatment.


Q: How does Fluores interact with alcohol consumption?

While there is no known direct interaction, alcohol may worsen common side effects of Fluores, such as headache, dizziness, or upset stomach. Alcohol consumption may also increase the risk of liver strain.


Q: Can Fluores interfere with my birth control?

Fluores is generally not expected to affect the effectiveness of combined oral contraceptives (the pill). However, official product information indicates that the drug may rarely increase the blood levels of the hormones present in some forms of birth control.


Q: Can Fluores affect my blood pressure?

While not a primary effect, adverse reactions mentioned in regulatory documents, such as those related to adrenal insufficiency or severe cardiovascular events, may rarely include symptoms like unusually low blood pressure.


Q: What is the reason Fluores is sometimes given with another medicine?

Fluores is sometimes administered in combination with other medications. This practice may be used to address co-occurring conditions, manage potential side effects, or to work synergistically with the other medication.


Q: Can I use Fluores if I have a known allergy to other medications?

Fluores is strictly contraindicated if you have a known allergy to its active ingredient, fluconazole, or any excipients. Official guidance indicates that information regarding all known allergies, including those to other medicines, foods, or additives, should be disclosed as part of the prescribing process.


Q: Why do official documents include the dose reduction rule for kidney problems?

The drug is primarily cleared from the body by the kidneys. Because impaired kidney function may cause the medication to build up to higher-than-intended levels, official protocols describe a lower maintenance dose for this population.


Q: What kind of monitoring (e.g., blood tests) might be needed while taking Fluores?

Official warnings indicate that for extended use, blood work—often including checks on liver function—may be necessary. This monitoring helps assess how the treatment is being tolerated.


Q: What kind of evidence led to Fluores' approval by the FDA/EMA?

The initial approval for Fluores (fluconazole) was based on pivotal clinical trials. These studies provided the necessary data for regulators to determine that the drug met the standards for safety and efficacy for the listed fungal and yeast infections.


Q: I've heard Fluores is a 'newer' drug. How much research evidence is actually available?

Fluores (fluconazole) was originally approved in the United States in 1990. It has been used for many years and is supported by a large volume of clinical use, trial data, and long-term post-marketing surveillance.


Q: Are there different strengths of Fluores, and what does the official source say about them?

The official source indicates that Fluores is manufactured in multiple standard strengths to accommodate different treatment protocols. These are available in solid forms and as a powder used to create a liquid oral suspension.


Q: Does the time of day I take Fluores matter?

Official guidance describes that taking Fluores at a consistent time each day may help maintain a steady level of the medicine in the body. The medication can be administered with or without food.


Q: I heard Fluores is a Schedule [X] drug. What does that mean for me?

Fluores (fluconazole) is not classified as a controlled substance under the U.S. Controlled Substances Act (DEA Schedule) and does not have the corresponding restrictions on dispensing and refills.


Q: Can Fluores be crushed or mixed with food if swallowing is difficult?

The capsules should typically be swallowed whole. If swallowing is difficult, a liquid oral suspension is available and should be measured accurately using a special device. There is no official guidance to crush the solid dosage forms.

How should Fluores be stored and disposed of?

How to Store and Dispose of Fluores?

Regulatory documentation defines strict storage and disposal requirements for Fluconazole (Fluores) to maintain product quality and safety.


Official Storage Constraints

Formulation Required Storage Condition
Capsules/Tablets Store below 30 C (86 F) and away from moisture.
Oral Suspension (Reconstituted) Store below 30 C. Do not freeze. Discard any unused portion after 14 days.
All Forms Keep the medicine in its original, tightly closed container.

Safety and Disposal Rules

All Fluconazole forms must be stored out of the sight and reach of children. Unused or expired medication must not be thrown in household trash or poured down the drain. Disposal should follow the specific pharmaceutical guidelines provided by a healthcare professional or pharmacist, adhering to local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluores found in:

A-Z Index: